#JustTheData is a new series by Cancer Communicator delivering an easy-to-read snapshot of recently presented clinical trial data.
STUDY DESIGN
Eligibility
≥18 years; histologically confirmed ccRCC +/- sarcomatoid features; increased risk of recurrence; ECOG PS of 0 or 1; nephrectomy and/or metastasectomy ≤12 weeks before randomization; No prior systemic therapy for RCC
Randomization (1:1); N = 994
Pembrolizumab 200 mg q3 wks for ≥17 cycles (~1 yr); n=496
Placebo; n=498
Primary Endpoint
Investigator-assessed DFS
KEY EFFICACY RESULTS
57.2 mo follow-up
Choueiri TK, et al. J Clin Oncol. 2024;42(suppl 4):LBA359.
Comments